Ticagrelor (Brilique; AstraZeneca), an oral antiplatelet therapy, was granted marketing
authorization by the European Commission in December 2010 for the prevention of …

Objective: This study aims to investigate the clinical efficacy of ticagrelor in patients who
underwent emergency percutaneous coronary intervention (PCI) for acute myocardial …

Background Bleeding complications are associated with unfavorable outcomes in patients
with acute coronary syndrome (ACS). Compared to Whites, several studies demonstrated a …

Background The relative merits of ticagrelor as compared with prasugrel in patients with
acute coronary syndromes for whom invasive evaluation is planned are uncertain. Methods …

High on-treatment platelet reactivity (HTPR) is accompanied by an increased risk of adverse
outcomes. Direct comparison of the antiplatelet effects between ticagrelor and high-dose …

Background and aims International guidelines recommend ticagrelor over clopidogrel as
preferred antiplatelet agent in patients following coronary stenting. However, no large real …

Background: The risk/benefit tradeoff of dual antiplatelet therapy after percutaneous
coronary intervention may vary in East Asian patients as compared with their non-East Asian …

Stent thrombosis is a morbid complication following percutaneous coronary intervention
(PCI). Dual antiplatelet therapy significantly reduces stent thrombosis risk. However, the …

Objective In this study, a systematic evaluation was conducted to estimate the efficacy and
safety of ticagrelor for treating acute coronary syndrome (ACS) in general ACS patients and …

Ticagrelor has a greater antiplatelet efficacy than clopidogrel but may be accompanied by
an increased risk of bleeding. This study evaluated the antiplatelet effect and …